|
| 37208237 | Management of Lymph Node-positive Penile Cancer: A Systematic Review. | Eur Urol | 2024 |
| 37819776 | Comparative cost-effectiveness of contemporary treatment strategies for stage IIA seminoma. | J Natl Cancer Inst | 2024 |
| 36906413 | European Association of Urology-American Society of Clinical Oncology Collaborative Guideline on Penile Cancer: 2023 Update. | Eur Urol | 2023 |
| 38071107 | Systematic Review and Meta-analysis of Minimally Invasive Procedures for Surgical Inguinal Nodal Staging in Penile Carcinoma. | Eur Urol Focus | 2023 |
| 37977513 | Assessment of PD-L1, TROP2, and nectin-4 expression in penile squamous cell carcinoma. | Hum Pathol | 2023 |
| 37414595 | Circulating antigen-primed cytotoxic T-cells in patients with renal tumors treated with surgery. | Urol Oncol | 2023 |
| 36924119 | Dynamic assessment of serum chromogranin A and treatment response with abiraterone acetate in metastatic castration-resistant prostate cancer. | Prostate | 2023 |
| 34750052 | Collecting duct carcinoma: A single-institution retrospective study. | Urol Oncol | 2022 |
| 35540709 | What Is the Most Effective Management of the Primary Tumor in Men with Invasive Penile Cancer: A Systematic Review of the Available Treatment Options and Their Outcomes. | Eur Urol Open Sci | 2022 |
| 35641216 | Rational Second-Generation Antiandrogen Use in Prostate Cancer. | Oncologist | 2022 |
| 35690072 | Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). | Lancet Oncol | 2022 |
| 35654629 | When Shall I Ask for a Second Opinion in Specialized Centers and How Can I Find Them? Do I Need a Medical Therapy in My Disease Course? | Semin Oncol Nurs | 2022 |
| 36089822 | Radiographic paradoxical response in metastatic castrate-resistant prostate cancer (mCRPC) managed with new generation anti-androgens: a retrospective analysis. | Prostate | 2022 |
| 35948037 | NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. | J Natl Compr Canc Netw | 2022 |
| 35878715 | Radiation Therapy in Oligometastatic Prostate Cancer. | Int J Radiat Oncol Biol Phys | 2022 |
| 36251574 | Comparative cost-effectiveness of neoadjuvant chemotherapy regimens for muscle-invasive bladder cancer: Results according to VESPER data. | Cancer | 2022 |
| 34789480 | Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial. | Clin Cancer Res | 2022 |
| 32675015 | A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer. | Clin Genitourin Cancer | 2021 |
| 33824031 | A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma. | Eur Urol | 2021 |
| 33632570 | Radium-223 in the Third-Line Setting in Metastatic Castration-Resistant Prostate Cancer: Impact of Concomitant Use of Enzalutamide on Overall Survival (OS) and Predictors of Improved OS. | Clin Genitourin Cancer | 2021 |
| 34491815 | Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. | J Clin Oncol | 2021 |
| 34593526 | Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in <sup>11</sup>C-Choline-PET/CT-Identified Oligometastatic Castration-Resistant Prostate Cancer. | Clin Cancer Res | 2021 |
| 34232950 | Chemoimmunotherapy after progression on single-agent pembrolizumab for metastatic urothelial carcinoma: a case series. | Anticancer Drugs | 2021 |
| 34254332 | Chemotherapy with atezolizumab for small cell or neuroendocrine carcinoma of the prostate: A single institution experience. | Prostate | 2021 |
| 34108181 | A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer. | Clin Cancer Res | 2021 |
| 33347775 | Cost-Effectiveness Analysis of Pembrolizumab for Bacillus Calmette-Guérin-Unresponsive Carcinoma In Situ of the Bladder. | J Urol | 2021 |
| 31353875 | Is there any benefit in adding postoperative adjuvant concurrent radiotherapy and chemotherapy for penile cancer with regional lymph node metastasis? | Minerva Urol Nefrol | 2020 |
| 31928407 | Systematic Review and Meta-Analysis-Is there a Benefit in Using Neoadjuvant Systemic Chemotherapy for Locally Advanced Penile Squamous Cell Carcinoma? | J Urol | 2020 |
| 31986451 | A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. | Eur J Cancer | 2020 |
| 32766800 | Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials: A Systematic Review and Meta-analysis. | JAMA Netw Open | 2020 |
| 32176595 | Reply by Authors. | J Urol | 2020 |
| 32135513 | Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2020 |
| 32489901 | Penile cancer with visceral metastasis and p16/human papillomavirus positivity: An unusual case of long-term survival. | Urol Case Rep | 2020 |
| 31021376 | Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. | JAMA Oncol | 2019 |
| 30870501 | Clonal analyses of refractory testicular germ cell tumors. | PLoS One | 2019 |
| 30837548 | Shared and unique genomic structural variants of different histological components within testicular germ cell tumours identified with mate pair sequencing. | Sci Rep | 2019 |
| 30702441 | Ascorbic acid-induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma. | J Clin Invest | 2019 |
| 29102314 | Re: Targeting Renal Cell Carcinoma with a HIF-2 Antagonist. | Eur Urol | 2018 |
| 30077464 | Association Between Renal Cell Carcinoma and Myelodysplastic Syndromes: Epigenetic Underpinning? | Clin Genitourin Cancer | 2018 |
| 29858590 | Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer. | Prostate Cancer Prostatic Dis | 2018 |
| 30181416 | NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. | J Natl Compr Canc Netw | 2018 |
| 29574109 | Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma. | J Urol | 2018 |
| 29709664 | Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy. | J Urol | 2018 |
| 27992270 | Role of High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Men With Previously Treated Germ Cell Tumors. | J Clin Oncol | 2017 |
| 29149760 | Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases. | Eur J Cancer | 2017 |
| 28982750 | Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2017 |
| 28947870 | Low hypoxia inducible factor-1α (HIF-1α) expression in testicular germ cell tumors - a major reason for enhanced chemosensitivity? | Chin J Cancer Res | 2017 |
| 29264217 | Non-seminomatous germ cell tumor with bone metastasis only at diagnosis: A rare clinical presentation. | Asian J Urol | 2017 |
| 28561704 | New Developments and Challenges in Rare Genitourinary Tumors: Non-Urothelial Bladder Cancers and Squamous Cell Cancers of the Penis. | Am Soc Clin Oncol Educ Book | 2017 |
| 28870517 | Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma. | Clin Genitourin Cancer | 2017 |